Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose

Biotechnology and Bioengineering

Volumn 108, Issue 7, 2011, Pages 1591-1602

  Gramer, Michael J ^a   Eckblad, Jackie J ^a   Donahue, Ruth ^a   Brown, Joseph ^a   Shultz, Carrie ^a   Vickerman, Kent ^a   Priem, Patrick ^b   van den Bremer, Ewald T J ^b   Gerritsen, Jolanda ^b   van Berkel, Patrick H C ^b  

^a Genmab   (United States)

^b GENMAB   (Netherlands)

Author keywords

CHO cells; Galactose; Galactosylation; Glycosylation; Manganese chloride; Uridine

Indexed keywords

CHO CELL; GALACTOSE; GALACTOSYLATION; MANGANESE CHLORIDE; URIDINE;

ANTIBODIES; CELL CULTURE; CONCENTRATION (PROCESS); DROPS; GLUCOSE; MANGANESE;

CHLORINE COMPOUNDS;

ANTIBODY; FC RECEPTOR; GALACTOSE; GLUCOSE; LACTIC ACID; MANGANESE CHLORIDE; URIDINE;

ANIMAL CELL; ANTIBODY GALACTOSYLATION; ANTIBODY PRODUCTION; ARTICLE; BIOREACTOR; CARBOHYDRATE ANALYSIS; CELL CULTURE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CULTURE MEDIUM; FED BATCH CULTURE; NONHUMAN; PROCESS OPTIMIZATION; REACTION ANALYSIS; REACTION TIME;

ANIMALS; ANTIBODIES; BIOREACTORS; CHLORIDES; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA; GALACTOSE; GLYCOSYLATION; MANGANESE COMPOUNDS; RECOMBINANT PROTEINS; URIDINE;

EID: 79956155356     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23075     Document Type: Article

References (59)

1. Altamirano C, Illanes A, Becerra S, Cairo JJ, Godia F. 2006. Considerations on the lactate consumption by CHO cells in the presence of galactose. J Biotechnol 125: 547-556.
2. Andersen DC. 2004. Cell Culture Effects on the Glycosylation of Therapeutic Proteins. Bioprocess International. IBC Life Sciences, Boston.
3. Andersen DC, Goochee CF. 1995. The effect of ammonia on the O-linked glycosylation of granulocyte colony-stimulating factor produced by Chinese hamster ovary cells. Biotechnol Bioeng 47: 96-105.
4. Boyd PN, Lines AC, Patel AK. 1995. The effect of the removal of sialic acid, galactose, and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32: 1311-1318.
5. Butler M. 2006. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems. Cytotechnology 50: 57-76.
6. Cabrera G, Cremata JA, Valdes R, Garcia R, Gonzales Y, Montesino R, Gomez H, Gonzalez M. 2004. Influence of culture conditions on the N-glycosylation of a monoclonal antibody specific for recombinant hepatitis B surface antigen. Biotechnol Appl Biochem 41: 67-76.
7. Cayli A, Hirschmann F, Wirth M, Hauser H, Wagner R. 1999. Cell lines with reduced UDP-N-acetylhexosamine pool in the presence of ammonium. Biotechnol Bioeng 65: 192-200.
8. Chen P, Harcum SW. 2006. Effects of elevated ammonium on glycosylation gene expression in CHO cells. Metab Eng 8: 123-132.
9. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med 358: 1109-1117.
10. Clark KJR, Griffiths J, Bailey KM, Harcum SW. 2005. Gene-expression profiles for five key glycosylation genes for galactose-fed CHO cells expressing recombinant IL-4/13 cytokine trap. Biotechnol Bioeng 90: 568-577.
11. Conzelmann E, Sandhoff K. 1987. Glycolipid and glycoprotein degradation. Adv Enzymol 60: 89-216.
12. Crowell CK, Grampp GE, Rogers GN, Miller J, Scheinman RI. 2007. Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol Bioeng 96: 538-549.
13. 15N from ammonium into the N-linked oligosaccharides of an immunoadhesion glycoprotein expressed in Chinese hamster ovary cells. Glycobiology 9: 125-131.
14. Gawlitzek M, Ryll T, Lofgren J, Sliwkowski MB. 2000. Ammonium alters N-glycan structures of recombinant TNFR-IgG: Degradative versus biosynthetic mechanisms. Biotechnol Bioeng 68: 637-646.
15. Ghaderi D, Taylor RE, Pedler-Karavani V, Diaz S, Varki A. 2010. Implications of the presence of N-glycoylneuraminic acid in recombinant therapeutic proteins. Nat Biotechnol 28: 863-867.
16. Gillmeister MP, Tomiya N, Jacobia SJ, Lee YC, Gorfien SF, Betenbaugh MJ. 2009. An HPLC-MALDI MS method for N-glycan analyses using smaller size samples: Application to monitor glycan modulation by medium conditions. Glyconj J 26: 1135-1149.
17. Godoy-Silva RG, Chalmers JJ, Casnocha SA, Bass LA, Ma N. 2009. Physiological responses of CHO cells to repetitive hydrodynamic stress. Biotechnol Bioeng 103: 1103-1117.
18. Goochee CF, Gramer MJ, Andersen DC, Bahr JB, Rasmussen JR. 1991. The oligosaccharides of glycoproteins: Bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Bio/Technology 9: 1347-1355.
19. Gramer MJ, Goochee CF. 1993. Glycosidase activities in Chinese hamster ovary cell lysate and cell culture supernatant. Biotechnol Prog 9: 366-373.
20. Grammatikos SI, Valley U, Nimtz M, Conradt HS, Wagner R. 1998. Intracellular UDP-N-acetlyhexosamine pool affects N-glycan complexity: A mechanism of ammonium action on protein glycosylation. Biotechnol Prog 14: 410-419.
21. Hills AE, Patel A, Boyd P, James DC. 2001. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol Bioeng 75: 239-251.
22. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21: 1644-1652.
23. Hong JK, Cho SM, Yoon SW. 2010. Substitution of glutamine by glutamate enhances production and galactosylation of recombinant IgG in Chinese hamster ovary cells. Appl Microbiol Biotechnol 88: 869-876.
24. Hossler P, Khattak SF, Li ZJ. 2009. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19: 936-949.
25. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21: 11-16.
26. Jefferis R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8: 226-234.
27. Kanda Y, Yamada T, Katsuhiro M, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M. 2006. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17: 104-118.
28. Kaneko Y, Nimmerjahn F, Ravetch JV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
29. Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB. 1994. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 5: 143-151.
30. Kunkel JP, Jan DCH, Jamieson JC, Butler M. 1998. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J Biotechnol 62: 55-71.
31. Kunkel JP, Jan DCH, Butler M, Jamieson JC. 2000. Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in different bioreactors. Biotechnol Prog 16: 462-470.
32. Lund J, Takahashi N, Nakagawa H, Goodall M, Bentley T, Hindley SA, Tyler R, Jefferis R. 1993. Control of IgG/Fc glycosylation: A comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol Immunol 30: 741-748.
33. Lund J, Takahashi N, Popplewell A, Goodall M, Pound JD, Tyler R, King DJ, Jefferis R. 2000. Expression and characterization of truncated forms of humanized L243 IgG1. Eur J Biochem 267: 7246-7256.
34. Majid FAA, Butler M, Al-Rubeai M. 2007. Glycosylation of an immunoglobulin produced from a murine hybridoma cell line: The effect of culture mode and the anti-apoptotic gene bcl-2. Biotechnol Bioeng 2007: 156-169.
35. Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter-Katalinic J. 2003. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng 83: 321-334.
36. Patel TP, Parekh RB, Moellering BJ, Prior CP. 1992. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J 285: 839-845.
37. Peipp M, van Bueren JJL, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, Repp R, van Berkel PHC, Vink T, van de Winkel JGJ, Parren PWHI, Valerius T. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
38. Pels Rijcken WR, Overdijk B, van den Eijnden DH, Ferwerda W. 1995. The effect of increasing nucleotide sugars into glycoconjugates in rat hepatocytes. Biochem J 305: 865-870.
39. Prater BD, Connelly HM, Qin Q, Cockrill SL. 2009. High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry. Anal Biochem 385: 69-79.
40. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, Lee DM, Rudd PM, Dwek RA. 2008. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 376: 1-12.
41. Ryll T. 2003. Galactosylation of recombinant glycoproteins. US Patent Application 20030211573.
42. Ryll T, Valley U, Wagner R. 1994. Biochemistry of growth inhibition by ammonium ions in mammalian cells. Biotechnol Bioeng 44: 184-193.
43. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44: 1524-1534.
44. Schmelzer AE, Miller WM. 2002. Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content. Biotechnol Prog 18: 346-353.
45. Serrato JA, Hernandez V, Estrada-Mondaca S, Palomares LA, Ramirez OT. 2007. Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media. Biotechnol Appl Biochem 47: 113-124.
46. Schilling BM, Gangloff S, Kothari D, Leister K, Matlock L, Zegarelli SG, Joosten CE, Basch JD, Sakhamuri S, Lee SS. 2008. Production quality enhancements in mammalian cell culture process for protein production. US Patent 7, 332, 303.
47. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcRγIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740.
48. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 3466-3473.
49. Siemiatkoski J, Lyubarskaya Y, Houde D, Tep S, Mhatre R. 2006. A comparison of three techniques for quantitative carbohydrate analysis used in characterization of therapeutic antibodies. Carbohydr Res 341: 410-419.
50. Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, Takeuchi F, Miyamoto T, Kobata A. 1989. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol 16: 285-290.
51. Valley U, Nimtz M, Conradt HS, Wagner R. 1999. Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. Biotechnol Bioeng 64: 401-417.
52. van Berkel PHC, Gerritsen J, Perdok G, Valbjorn J, Vink T, van de Winkel JGJ, Parren PWHI. 2009. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol Prog 25: 244-251.
53. van Berkel PHC, Gerritsen J, van Voskuilen E, Perdok G, Vink T, van de Winkel JGJ, Parren PWHI. 2010. Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system. Biotechnol Bioeng 105: 350-357.
54. Wong NSC, Wati L, Nissom PM, Feng HT, Lee MM, Yap MGS. An investigation of intracellular glycosylation activities in CHO cells: Effects of nucleotide sugar precursor feeding. Biotechnol Bioeng 107: 321-336.
55. Wong DCF, Wong NSC, Goh JSY, May LM, Yap MGS. 2010. Profiling of N-glycosylation gene expression in CHO fed-batch cultures. Biotechnol Bioeng 107: 516-528.
56. Wright A, Morrison SL. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human IgG1. J Expt Med 180: 1087-1096.
57. Wright A, Morrison SL. 1998. Effect of C2-associated carbohydrate structure on Ig effector function: Studies in chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160: 3393-3402.
58. Yang M, Butler M. 2002. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog 18: 129-138.
59. Zhou Q, Shankara S, Roy A, Qui H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. 2008. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99: 652-665.